Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05948683 · ClinicalTrials.gov registry record · Early Phase 1

Prosocial Effects of MDMA

A Early Phase 1 study of Social Interaction and MDMA ('Ecstasy'), sponsored by University of Chicago.

Completed
Registry status
Early Phase 1
Development phase
33
Enrollment target
1
Study location

NCT05948683 is a Early Phase 1 study of Social Interaction and MDMA ('Ecstasy') that has completed, run by University of Chicago. The registered enrollment target is 33 participants, below the 620-participant average among 3 other Social Interaction trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05948683, a Early Phase 1 study of Social Interaction and MDMA ('Ecstasy'), has completed, sponsored by University of Chicago.

COMPLETED
Registry status
Early Phase 1
Development phase
33 participants
Enrollment target
1
Study location

Study Summary

In this study, the aim is to test the hypothesis that MDMA produces greater prosocial effects when administered in the presence of a familiar, compared to an unfamiliar, person

Interventions

  • DRUG Placebo
  • DRUG MDMA

Study Locations (1)

Illinois

  • University of Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 33 participants
Start Date 2023-07-21
Est. Completion 2024-07-15
Phase Early Phase 1

Sponsor

University of Chicago

796 total trials

What the Registry Record Tells You About NCT05948683

The ClinicalTrials.gov registry entry for NCT05948683 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 620-participant average among 3 other Social Interaction trials with a reported enrollment target (95% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Social Interaction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05948683 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT05948683 about?

NCT05948683 is a clinical study titled "Prosocial Effects of MDMA". In this study, the aim is to test the hypothesis that MDMA produces greater prosocial effects when administered in the presence of a familiar, compared to an unfamiliar, person

What is the current status of trial NCT05948683?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 33 participants. The study started on 2023-07-21. Estimated completion is 2024-07-15.

What conditions does trial NCT05948683 study?

This clinical trial studies the following conditions: Social Interaction, MDMA ('Ecstasy').

What interventions are being tested in trial NCT05948683?

The interventions under investigation include: Placebo (DRUG), MDMA (DRUG).

Who is sponsoring clinical trial NCT05948683?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05948683 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Social Interaction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.